AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test AssureRx Wellness, Inc red blood cells http://prednisolone20mg.net ., a personalized medicine company centered on pharmacogenetics to assist in the treatment of patients with psychiatric disorders, announced that it offers added a fifth gene today, CYP1A2, to its laboratory-developed pharmacogenetic test. The CYP1A2 gene is definitely involved in the metabolism of several commonly used drugs, including antipsychotics and antidepressants. The up to date 5-gene test, a web-structured therapeutic decision support product, analyzes genetic variants which might affect a patient’s ability to tolerate or react to psychotropic medicines. GeneSightRx integrates the analysis of genes and their many variants to acquire an evidence-based pharmacogenetic profile.
LLC is acting as the only real Book-Running Manager for the offering.. Asterias Biotherapeutics prices underwritten community offering of common share at $3.90 per share Asterias Biotherapeutics, Inc. , a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten open public providing of its common stock at a cost of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common share at the same cost as the underwritten general public offering. Gross proceeds to the business from the public providing and the personal placement are anticipated to be approximately $5.5 million in the aggregate. Closing of the public offering is scheduled for February 10, 2015 subject to customary closing conditions.